PRME
Price
$3.39
Change
+$0.15 (+4.63%)
Updated
Aug 21 closing price
Capitalization
614.87M
68 days until earnings call
Intraday BUY SELL Signals
STTK
Price
$7.53
Change
+$0.28 (+3.86%)
Updated
Aug 21 closing price
Capitalization
755.74M
79 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PRME vs STTK

PRME vs STTK Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
PRME vs. STTK commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Hold and STTK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (PRME: $3.39 vs. STTK: $7.53)
Brand notoriety: PRME and STTK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 92% vs. STTK: 28%
Market capitalization -- PRME: $614.87M vs. STTK: $755.74M
PRME [@Biotechnology] is valued at $614.87M. STTK’s [@Biotechnology] market capitalization is $755.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $138.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 1 FA rating(s) are green whileSTTK’s FA Score has 0 green FA rating(s).

  • PRME’s FA Score: 1 green, 4 red.
  • STTK’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than STTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 4 TA indicator(s) are bullish while STTK’s TA Score has 3 bullish TA indicator(s).

  • PRME’s TA Score: 4 bullish, 5 bearish.
  • STTK’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both PRME and STTK are a bad buy in the short-term.

Price Growth

PRME (@Biotechnology) experienced а +9.71% price change this week, while STTK (@Biotechnology) price change was +1.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.

Reported Earning Dates

PRME is expected to report earnings on Oct 30, 2026.

STTK is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STTK($756M) has a higher market cap than PRME($615M). STTK YTD gains are higher at: 106.301 vs. PRME (-2.305). STTK has higher annual earnings (EBITDA): -49.02M vs. PRME (-199.14M). PRME has more cash in the bank: 135M vs. STTK (90.4M). STTK has less debt than PRME: STTK (2.89M) vs PRME (115M). PRME has higher revenues than STTK: PRME (4.03M) vs STTK (1M).
PRMESTTKPRME / STTK
Capitalization615M756M81%
EBITDA-199.14M-49.02M406%
Gain YTD-2.305106.301-2%
P/E RatioN/AN/A-
Revenue4.03M1M403%
Total Cash135M90.4M149%
Total Debt115M2.89M3,981%
FUNDAMENTALS RATINGS
PRME vs STTK: Fundamental Ratings
PRME
STTK
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
4734
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (31) in the null industry is somewhat better than the same rating for STTK (64). This means that PRME’s stock grew somewhat faster than STTK’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as STTK (100). This means that PRME’s stock grew similarly to STTK’s over the last 12 months.

STTK's SMR Rating (99) in the null industry is in the same range as PRME (100). This means that STTK’s stock grew similarly to PRME’s over the last 12 months.

STTK's Price Growth Rating (34) in the null industry is in the same range as PRME (47). This means that STTK’s stock grew similarly to PRME’s over the last 12 months.

STTK's P/E Growth Rating (100) in the null industry is in the same range as PRME (100). This means that STTK’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMESTTK
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 13 days ago
81%
Bullish Trend 5 days ago
86%
Declines
ODDS (%)
Bearish Trend 10 days ago
88%
Bearish Trend 18 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
PRME
Daily Signal:
Gain/Loss:
STTK
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EMGDX42.190.79
+1.91%
Allspring Emerging Markets Equity R6
EILGX17.090.14
+0.83%
Eaton Vance Atlanta Capital Focused Gr I
GSIYX24.110.11
+0.46%
Goldman Sachs GQG Ptnrs Intl Opps R6
RPFRX41.480.04
+0.10%
Davis Real Estate A
JDSRX26.25N/A
N/A
Janus Henderson Small Cap Value R

STTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STTK has been loosely correlated with VRTX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if STTK jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STTK
1D Price
Change %
STTK100%
+3.86%
VRTX - STTK
36%
Loosely correlated
+1.44%
ADCT - STTK
35%
Loosely correlated
+3.80%
PRME - STTK
34%
Loosely correlated
+4.63%
CELC - STTK
33%
Poorly correlated
+3.27%
BEAM - STTK
33%
Poorly correlated
+4.83%
More